MEDIGEN VACCINE BIOLOGICS CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52 TWD | -0.95% |
|
+3.59% | -25.82% |
| Sales 2022 | 365.04 11.89K | Sales 2023 | 389.62 12.69K | Capitalization | 23.04B 750B |
|---|---|---|---|---|---|
| Net income 2022 | -1.48B -48.04B | Net income 2023 | -1.16B -37.78B | EV / Sales 2022 | 56,167,962 x |
| Net cash position 2022 | 2.28B 74.3B | Net cash position 2023 | 1.78B 58.06B | EV / Sales 2023 | 54,546,582 x |
| P/E ratio 2022 |
-15.2
x | P/E ratio 2023 |
-19.8
x | Employees | 103 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.37% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.95% | ||
| 1 week | +3.59% | ||
| 1 month | -2.80% | ||
| 3 months | -15.31% | ||
| 6 months | -26.66% | ||
| Current year | -25.82% |
1 week
48.75
53.10
1 month
48.0553.30
Current year
48.0570.70
1 year
48.0581.50
3 years
48.05281.22
5 years
18.21281.22
10 years
16.19281.22
| Managers | Title | Age | Since |
|---|---|---|---|
Tsan Chien Chen
CEO | Chief Executive Officer | - | 12-12-11 |
Yu Ping Yang
DFI | Director of Finance/CFO | - | 14-08-14 |
Stanley Chang
CHM | Chairman | 81 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stanley Chang
CHM | Chairman | 81 | - |
Tsan Chien Chen
CEO | Chief Executive Officer | - | 12-12-11 |
Ming Cheng Chang
BRD | Director/Board Member | 69 | 15-09-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.01% | 117 M€ | +0.16% | - | |
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 52 | -0.95% | 944,489 |
| 24-04-24 | 52.5 | +4.37% | 1,736,234 |
| 24-04-23 | 50.3 | +2.34% | 930,586 |
| 24-04-22 | 49.15 | +1.34% | 1,193,543 |
| 24-04-19 | 48.5 | -3.39% | 1,680,825 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes
Medigen Vaccine Biologics Corporation is a Taiwan-based company principally engaged in the development and manufacturing of vaccines and biological agents. The Company is engaged in the development of cutting edge technologies for cell-based human vaccines production. For vaccine development, the Company has established the manufacturing process for H1N1 and H5N1. Further, it also conducts clinical trials to confirm safety and efficacy of produced vaccines. In addition, the Company is also engaged in biological agents business.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.82% | 524M | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +56.02% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.49% | 8.75B |
- Stock Market
- Equities
- 6547 Stock
